We reanalyzed the 7-valent pneumococcal conjugate vaccine trial FinOM for prevention of acute otitis media (AOM), with a focus on disease replacement due to other pathogens and AOM recurrence. We found evidence of replacement disease occurring early during the trial follow-up and little vaccine impact on recurrent overall AOM episodes.